

PD-L1 Polyclonal Antibody

catalog number: E-AB-65810

Note: *Centrifuge before opening to ensure complete recovery of vial contents.*

Description


Reactivity	Human;Mouse;Rat
Immunogen	Recombinant fusion protein of human PD-L1 (NP_054862.1).
Host	Rabbit
Isotype	Rabbit IgG
Purification	Affinity purification
Buffer	Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol.

Applications


Recommended Dilution

IHC	1:50-1:200
-----	------------


Data



Immunohistochemistry of paraffin-embedded Human colon carcinoma using PD-L1 Polyclonal Antibody at dilution of 1:100 (40x lens).



Immunohistochemistry of paraffin-embedded Mouse spleen using PD-L1 Polyclonal Antibody at dilution of 1:100 (40x lens).



Immunohistochemistry of paraffin-embedded Rat spleen using PD-L1 Polyclonal Antibody at dilution of 1:100 (40x lens).

Preparation & Storage

Storage	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Shipping	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Background

For Research Use Only

Toll-free: 1-888-852-8623
Web: www.elabscience.com

Tel: 1-832-243-6086
Email: techsupport@elabscience.com

Fax: 1-832-243-6017

Rev. V1.7

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.